CN105682671A - 用于管理癌症和治疗癌症并存病的方法 - Google Patents

用于管理癌症和治疗癌症并存病的方法 Download PDF

Info

Publication number
CN105682671A
CN105682671A CN201480060350.5A CN201480060350A CN105682671A CN 105682671 A CN105682671 A CN 105682671A CN 201480060350 A CN201480060350 A CN 201480060350A CN 105682671 A CN105682671 A CN 105682671A
Authority
CN
China
Prior art keywords
extract
cancer
species extract
weight
species
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480060350.5A
Other languages
English (en)
Chinese (zh)
Inventor
S·哈尔蒂
J·刘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suisse Switzerland Co ltd
Original Assignee
Legacy Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Legacy Healthcare Ltd filed Critical Legacy Healthcare Ltd
Priority to CN202211114854.3A priority Critical patent/CN115350236A/zh
Publication of CN105682671A publication Critical patent/CN105682671A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/577—Malvaceae (Mallow family)
    • A61K36/5777—Theobroma, e.g. cocao or cocoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201480060350.5A 2013-11-08 2014-11-07 用于管理癌症和治疗癌症并存病的方法 Pending CN105682671A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211114854.3A CN115350236A (zh) 2013-11-08 2014-11-07 用于管理癌症和治疗癌症并存病的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361901631P 2013-11-08 2013-11-08
US61/901,631 2013-11-08
PCT/EP2014/074048 WO2015067759A1 (en) 2013-11-08 2014-11-07 Method for the management of cancer and treatment of cancer comorbidities

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202211114854.3A Division CN115350236A (zh) 2013-11-08 2014-11-07 用于管理癌症和治疗癌症并存病的方法

Publications (1)

Publication Number Publication Date
CN105682671A true CN105682671A (zh) 2016-06-15

Family

ID=51868963

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480060350.5A Pending CN105682671A (zh) 2013-11-08 2014-11-07 用于管理癌症和治疗癌症并存病的方法
CN202211114854.3A Pending CN115350236A (zh) 2013-11-08 2014-11-07 用于管理癌症和治疗癌症并存病的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202211114854.3A Pending CN115350236A (zh) 2013-11-08 2014-11-07 用于管理癌症和治疗癌症并存病的方法

Country Status (16)

Country Link
US (2) US10357531B2 (enExample)
EP (1) EP3065751B1 (enExample)
JP (1) JP6742904B2 (enExample)
KR (1) KR102344748B1 (enExample)
CN (2) CN105682671A (enExample)
AU (1) AU2014345539B2 (enExample)
BR (1) BR112016009931B1 (enExample)
CA (1) CA2928675C (enExample)
DK (1) DK3065751T3 (enExample)
ES (1) ES2777250T3 (enExample)
HK (1) HK1223844A1 (enExample)
MX (1) MX2016006006A (enExample)
PL (1) PL3065751T3 (enExample)
PT (1) PT3065751T (enExample)
RU (1) RU2016117205A (enExample)
WO (1) WO2015067759A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113164440A (zh) * 2018-11-30 2021-07-23 贝斯以色列女执事医疗中心有限公司 减少癌症患者的主要血栓事件的组合物和方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2862598A1 (en) 2013-10-16 2015-04-22 Legacy Healthcare Holding Ltd. Use of a composition for the pigmentation of hair and hairs
WO2017186954A1 (en) * 2016-04-28 2017-11-02 Legacy Healthcare Ltd Method for the improvement of speed and endurance capacity
FR3109881B1 (fr) * 2020-05-07 2022-10-21 Legacy Healthcare Switzerland Sa Procede pour ameliorer le systeme immun pour acquerir la pan-immunite
US11819530B1 (en) 2023-05-17 2023-11-21 Legacy Healthcare (Switzerland) Sa Long term treatment of hair loss

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101631529A (zh) * 2007-02-13 2010-01-20 传世健康护理控股有限公司 新型化妆品和/或药物组合物及它们的应用
CN102578509A (zh) * 2004-03-19 2012-07-18 雀巢技术公司 功能性成分的提供
WO2012113820A1 (en) * 2011-02-23 2012-08-30 Legacy Healthcare Holding Ltd New use of compositions for preventing chemotherapy and radiotherapy induced alopecia (cria), reducing cria impact and improving the appearance of hair re-growth after cria
WO2013020719A2 (en) * 2011-08-09 2013-02-14 Legacy Healthcare Holding Ltd New use of compositions to delay the onset of the catagen phase of the hair

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2844614A1 (de) 1978-10-13 1980-05-08 Alfred Czypull Bio-aktiv-haartinktur
JPH04342517A (ja) 1990-07-20 1992-11-30 Yutaka Miyauchi ５α−リダクターゼ阻害剤
CH682217A5 (en) 1991-05-23 1993-08-13 Linda Singer Dolla Hair lotion comprising aq. alcoholic extract of natural plant material - and aromatic plant substances and prepn., for treating or preventing baldness
FR2706771A1 (en) 1993-06-21 1994-12-30 Pelletier Jacques Formula for the treatment of certain cancers.
JP3233813B2 (ja) 1995-03-31 2001-12-04 株式会社マンダム チロシナーゼ生合成促進剤及び白髪改善用又は白髪防止用頭髪用化粧料並びに日焼け用化粧料
DE19533777A1 (de) 1995-09-12 1997-03-13 Walther Aria Ellen Haarwuchsmittel
JP3527584B2 (ja) 1996-01-23 2004-05-17 株式会社ナリス化粧品 養毛・育毛剤
US5773241A (en) 1996-09-05 1998-06-30 Ericsson; Arthur Dale Preparation of bioactive extracts
JP2000044439A (ja) 1998-07-31 2000-02-15 Shiseido Co Ltd 頭皮頭髪用組成物
JP2000247830A (ja) 1999-02-26 2000-09-12 Nagase & Co Ltd エラスターゼ阻害剤
EP1228769A1 (de) 2001-02-02 2002-08-07 Jörg-Peter Prof. Schür Symbiontisches Regenerativum
US6582702B2 (en) * 2001-07-10 2003-06-24 Alvin Foster Rigby Herbal tonic composition that improves respiration, aids in the elimination of toxins and improves overall vitality
US20030077336A1 (en) 2001-10-10 2003-04-24 Maf Group, Llc Anti-inflammatory complex containing flaxseed oil
JP2003201229A (ja) 2001-10-23 2003-07-18 Shiseido Co Ltd マトリックスメタロプロテアーゼ活性阻害剤および抗老化用化粧料
US20030105104A1 (en) * 2001-11-27 2003-06-05 Burzynski Stanislaw R. Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy
BR0203591A (pt) * 2002-09-05 2004-05-25 Marc Kipfer Bebida reidratante e energética natural a base de água-de-coco, sucos de frutas e componentes nutritivos incorporados
DE102004011968A1 (de) 2004-03-10 2005-09-29 Henkel Kgaa Präbiotisch wirksame Pflanzenextrakte
KR20070022018A (ko) 2004-03-19 2007-02-23 네스텍소시에테아노님 기능성 재료의 전달
EP1604647B1 (en) 2004-05-12 2008-05-07 Chisso Corporation Cosmetic composition containing polyorganosiloxane-containing epsilon-polylysine polymer, and polyhydric alcohol, and production thereof
WO2005120452A1 (en) 2004-06-07 2005-12-22 Katica Pavlovic A procedure in production of a curative creams for regeneration of skin tissue, easer breathing, psoriasis, pains and tiredness in legs
FR2865132A1 (fr) 2004-07-06 2005-07-22 Oreal Utilisation de la diosmetine, d'un de ses derives ou d'un extrait de plante contenant l'un d'eux pour favoriser la pigmentation de la peau et/ou des cheveux
DE202004012348U1 (de) 2004-08-03 2004-10-07 Jabal Amman, Suhbi Hasan Mohammes Zubereitung zur Pflege der Haut bei Psoriasis oder Ekzem
US7462595B2 (en) * 2004-09-17 2008-12-09 Prange Jr Arthur Jergen Methods for treating cancer-related fatigue
JP2006104098A (ja) 2004-10-04 2006-04-20 Ichimaru Pharcos Co Ltd ヒアルロニダーゼ活性阻害剤
FR2877219B1 (fr) 2004-10-28 2007-03-09 Fatima Basri Composition utilisee en cosmetique ou en pharmacologie pour stimuler la synthese du collagene
FR2877576B1 (fr) 2004-11-08 2007-03-09 Ahmed Kadri Composition pharmaceutique utilisee pour stimuler la proliferation et l'activation des mastocytes
DE102005010142A1 (de) 2005-03-02 2005-11-03 Dr. Kurt Wolff Gmbh & Co. Kg Mittel zur Aktivierung der Haarwurzeln und Verwendung des Mittels
JP4804805B2 (ja) 2005-06-10 2011-11-02 横関油脂工業株式会社 細胞賦活剤、紫外線障害緩和剤及びメラニン産生抑制剤
WO2008015341A2 (fr) 2006-08-03 2008-02-07 Societe D'extraction Des Principes Actifs Sa (Vincience) Utilisation d'un extrait vegetal en tant qu'agent actif pour augmenter la synthese de melanine dans les melanocytes
US8088431B2 (en) * 2007-03-14 2012-01-03 The Hershey Company Health bars and compositions for improving mental and physical energy
US20080305096A1 (en) 2007-06-07 2008-12-11 Unicity International, Inc. Method and composition for providing controlled delivery of biologically active substances
FR2939646B1 (fr) 2008-12-12 2017-04-14 Oreal Procede de coloration capillaire a partir d'une composition comprenant au moins un orthodiphenol, un sel metallique, du peroxyde d'hydrogene, du (bi)carbonate et un agent alcalinisant
AU2010270971B2 (en) * 2009-06-22 2015-08-20 Sk Biopharmaceuticals Co., Ltd. Methods for treating or preventing fatigue
WO2011005311A1 (en) * 2009-07-07 2011-01-13 Robert Shorr Pharmaceutical composition
CN103313693A (zh) 2010-08-05 2013-09-18 传世健康护理控股有限公司 用于刺激毛发生长的方法
WO2012140013A2 (en) 2011-04-11 2012-10-18 Legacy Healthcare Holding Ltd New use of compositions for the treatment of inflammatory skin conditions, scaly scalp conditions and collagen remodeling.
EP2862598A1 (en) 2013-10-16 2015-04-22 Legacy Healthcare Holding Ltd. Use of a composition for the pigmentation of hair and hairs

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102578509A (zh) * 2004-03-19 2012-07-18 雀巢技术公司 功能性成分的提供
CN101631529A (zh) * 2007-02-13 2010-01-20 传世健康护理控股有限公司 新型化妆品和/或药物组合物及它们的应用
WO2012113820A1 (en) * 2011-02-23 2012-08-30 Legacy Healthcare Holding Ltd New use of compositions for preventing chemotherapy and radiotherapy induced alopecia (cria), reducing cria impact and improving the appearance of hair re-growth after cria
WO2013020719A2 (en) * 2011-08-09 2013-02-14 Legacy Healthcare Holding Ltd New use of compositions to delay the onset of the catagen phase of the hair

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
刘宏森: "《根茎类蔬菜的经济价值》", 31 March 2010, 天津科技翻译出版公司 *
奚华: "《酒店餐饮金牌服务员培训手册 最新版》", 30 November 2007, 中国商业出版社 *
顾维维: "《怎样选择保健食品》", 31 August 2002, 上海人民出版社 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113164440A (zh) * 2018-11-30 2021-07-23 贝斯以色列女执事医疗中心有限公司 减少癌症患者的主要血栓事件的组合物和方法

Also Published As

Publication number Publication date
WO2015067759A1 (en) 2015-05-14
KR20160074006A (ko) 2016-06-27
US20160256512A1 (en) 2016-09-08
MX2016006006A (es) 2016-07-18
EP3065751B1 (en) 2019-12-18
JP2016535753A (ja) 2016-11-17
US20190314441A1 (en) 2019-10-17
JP6742904B2 (ja) 2020-08-19
RU2016117205A3 (enExample) 2018-08-09
US10357531B2 (en) 2019-07-23
AU2014345539B2 (en) 2020-04-23
AU2014345539A8 (en) 2016-05-26
PL3065751T3 (pl) 2020-07-13
AU2014345539A1 (en) 2016-05-19
EP3065751A1 (en) 2016-09-14
HK1223844A1 (zh) 2017-08-11
RU2016117205A (ru) 2017-12-11
CA2928675C (en) 2023-09-05
PT3065751T (pt) 2020-03-06
BR112016009931B1 (pt) 2021-02-02
KR102344748B1 (ko) 2021-12-30
DK3065751T3 (da) 2020-03-09
ES2777250T3 (es) 2020-08-04
CA2928675A1 (en) 2015-05-14
CN115350236A (zh) 2022-11-18

Similar Documents

Publication Publication Date Title
US20190314441A1 (en) Method For The Management Of Cancer And Cancer Treatment-Related Comorbidities
RU2012148710A (ru) Органическое соединение для применения при лечении рака печени
JP2007518805A5 (enExample)
Ariel Therapeutic effects of hydroxyurea. Experience with 118 patients with inoperable solid tumors
JP5680412B2 (ja) レオヌリンの使用およびその組成物
WO2017148129A1 (zh) 一种用于治疗恶病质的药物组合物及其应用
Oettmeier et al. The procaine-base-infusion: 20 years of experience of an alternative use with several therapeutical effects
JP2024522163A5 (enExample)
HK40077741A (en) Method for the management of cancer and treatment of cancer comorbidities
EP1877043B1 (en) Use of paeonol for inhibiting angiogenesis or for enhancing radiosensitization
CN106421796B (zh) 索拉菲尼联合ccr4拮抗剂在抑制癌生长及转移中的应用
CN105769884B (zh) 一种治疗肺癌的药物组合物
JP2021533107A (ja) 癌を治療するための併用療法
CN118141867B (zh) 一种以鹿角人参为君药治疗乳腺癌的药物及制备方法和应用
CN117224514B (zh) 一种化合物、组合物及其在制备治疗心律失常的药物中的应用
KR102766591B1 (ko) 지방분해용 주사제 조성물
JP2021533112A (ja) 癌を治療するための併用療法
CN105193810B (zh) 5‑氟尿嘧啶组合物及其在制备抗肿瘤注射剂中的应用
KR102790590B1 (ko) 지방 분해용 조성물
CN103705547A (zh) 一种灵芝孢子的破壁处理剂
TW202000207A (zh) 膀胱癌用抗腫瘤劑及膀胱癌的處置方法
EP1203585A1 (en) Anti-ischemic agent
JP2024017060A (ja) Ｔｉｅ２活性化剤
JPH10175860A5 (enExample)
WO2022122040A1 (zh) 白果内酯或银杏内酯组合物在制备镇静药物中的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1223844

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20180509

Address after: Swiss ekpa lanri

Applicant after: Suisse (Switzerland) Co.,Ltd.

Address before: Valletta

Applicant before: LEGACY HEALTHCARE Ltd.

TA01 Transfer of patent application right
RJ01 Rejection of invention patent application after publication

Application publication date: 20160615

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1223844

Country of ref document: HK